US7846445B2
(en)
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8334257B2
(en)
|
2005-12-20 |
2012-12-18 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
CN101970678B
(zh)
|
2007-06-21 |
2014-08-20 |
慕尼黑科技大学 |
具有增加的体内和/或体外稳定性的生物学活性蛋白
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
EP2300045A1
(de)
|
2008-05-15 |
2011-03-30 |
Transmolecular, Inc. |
Behandlung von metastatischen tumoren
|
EP3412300A1
(de)
|
2008-06-27 |
2018-12-12 |
Duke University |
Therapeutika mit elastinähnlichen peptiden
|
US8703717B2
(en)
*
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
CN102348715B
(zh)
|
2009-02-03 |
2017-12-08 |
阿穆尼克斯运营公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
US8716448B2
(en)
*
|
2009-02-03 |
2014-05-06 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
EP2440241B1
(de)
*
|
2009-06-08 |
2017-08-09 |
Amunix Operating Inc. |
Wachstumshormon-polypeptide sowie verfahren zu ihrer herstellung und verwendung
|
US9849188B2
(en)
|
2009-06-08 |
2017-12-26 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
PT2440228T
(pt)
|
2009-06-08 |
2018-12-24 |
Amunix Operating Inc |
Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
CA2788824C
(en)
|
2010-02-04 |
2019-03-12 |
Morphotek, Inc. |
Chlorotoxin polypeptides and conjugates and uses thereof
|
WO2011123813A2
(en)
*
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
WO2011123830A2
(en)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
CN103097403B
(zh)
|
2010-05-11 |
2017-04-19 |
弗雷德哈钦森癌症研究中心 |
氯毒素变体、缀合物及其使用方法
|
CN102883734B
(zh)
|
2010-05-21 |
2018-01-02 |
Xl-蛋白有限责任公司 |
生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
|
US9238080B2
(en)
|
2010-05-21 |
2016-01-19 |
Merrimack Pharmaceuticals, Inc. |
Bi-specific fusion proteins
|
WO2011157819A2
(en)
|
2010-06-18 |
2011-12-22 |
Xiberscience Gmbh |
Peptides as active agents to stabilize biological barriers
|
AU2011283669A1
(en)
|
2010-07-29 |
2013-02-07 |
Eleven Biotherapeutics, Inc. |
Chimeric IL-1 receptor type I agonists and antagonists
|
ES2758352T3
(es)
|
2010-11-26 |
2020-05-05 |
Molecular Partners Ag |
Proteínas de repetición diseñadas que se une a la seroalbúmina
|
IL210093A0
(en)
*
|
2010-12-19 |
2011-06-30 |
David Helman |
Membrane bound reporter molecules and their use in cell sorting
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
WO2012170969A2
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
MY180714A
(en)
|
2011-07-08 |
2020-12-07 |
Bioverativ Therapeutics Inc |
Factor viii chimeric and hybrid polypeptides, and methods of use thereof
|
EA028914B1
(ru)
|
2011-07-25 |
2018-01-31 |
Байоджен Хемофилия Инк. |
Исследования для мониторинга нарушений свертываемости крови
|
CN104066439A
(zh)
|
2011-07-29 |
2014-09-24 |
十一生物治疗股份有限公司 |
纯化的蛋白质
|
CA2843504C
(en)
*
|
2011-08-12 |
2020-08-25 |
Ascendis Pharma A/S |
Protein carrier-linked prodrugs
|
CN103857413A
(zh)
|
2011-08-12 |
2014-06-11 |
阿森迪斯药物股份有限公司 |
载体连接的曲罗尼尔前药
|
NZ626945A
(en)
|
2012-01-12 |
2016-10-28 |
Biogen Ma Inc |
Chimeric factor viii polypeptides and uses thereof
|
US20130210747A1
(en)
|
2012-02-13 |
2013-08-15 |
University Of Southern California |
Methods and Therapeutics Comprising Ligand-Targeted ELPs
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
KR20190094480A
(ko)
|
2012-02-15 |
2019-08-13 |
바이오버라티브 테라퓨틱스 인크. |
재조합 인자 viii 단백질
|
CN117462693A
(zh)
|
2012-02-27 |
2024-01-30 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
EP3646880A1
(de)
|
2012-05-07 |
2020-05-06 |
Allergan, Inc. |
Verfahren zur behandlung von amd bei gegen eine anti-vegf-therapie unempfindlichen patienten
|
EP2858659B1
(de)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Prokoagulationsverbindungen
|
AU2013270683A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|
AU2013283296A1
(en)
|
2012-06-28 |
2015-02-05 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to platelet-derived growth factor
|
EP3404105A1
(de)
|
2012-07-06 |
2018-11-21 |
Bioverativ Therapeutics Inc. |
Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
|
PT2882450T
(pt)
|
2012-07-11 |
2020-02-19 |
Bioverativ Therapeutics Inc |
Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
|
WO2014026054A2
(en)
|
2012-08-10 |
2014-02-13 |
University Of Southern California |
CD20 scFv-ELPs METHODS AND THERAPEUTICS
|
US20140092376A1
(en)
*
|
2012-10-01 |
2014-04-03 |
Momentive Performance Materials, Inc. |
Container and method for in-line analysis of protein compositions
|
AU2013331000B2
(en)
|
2012-10-18 |
2018-04-19 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
WO2014070953A1
(en)
|
2012-10-30 |
2014-05-08 |
Biogen Idec Ma Inc. |
Methods of Using FVIII Polypeptide
|
WO2014081849A1
(en)
|
2012-11-20 |
2014-05-30 |
Phasebio Pharmaceuticals, Inc. |
Formulations of active agents for sustained release
|
EP2738180A1
(de)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Bindeproteine mit mindestens zwei Bindedomänen gegen HER2
|
CN105189540A
(zh)
|
2012-12-10 |
2015-12-23 |
弗莱德哈钦森癌症研究中心 |
含脂质运载蛋白融合伴侣
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
SI3889173T1
(sl)
|
2013-02-15 |
2023-11-30 |
Bioverativ Therapeutics Inc. |
Optimiran gen dejavnika VIII
|
PL2968468T3
(pl)
|
2013-03-13 |
2021-12-20 |
Buzzard Pharmaceuticals AB |
Preparaty chimerycznej cytokiny do dostarczania do oka
|
EP2968581A1
(de)
|
2013-03-14 |
2016-01-20 |
Medimmune Limited |
Pegylierte glucagon- und glp-1-coagonisten zur behandlung von adipositas
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
HUE047933T2
(hu)
|
2013-03-15 |
2020-05-28 |
Bioverativ Therapeutics Inc |
Faktor VIII polipeptid készítmények
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
EP4108254A1
(de)
|
2013-08-14 |
2022-12-28 |
Bioverativ Therapeutics Inc. |
Rekombinante faktor-viii-proteine
|
JP6463361B2
(ja)
|
2013-09-08 |
2019-01-30 |
コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. |
第viii因子両性イオンポリマーコンジュゲート
|
US11559580B1
(en)
|
2013-09-17 |
2023-01-24 |
Blaze Bioscience, Inc. |
Tissue-homing peptide conjugates and methods of use thereof
|
EP3903599A1
(de)
|
2013-09-25 |
2021-11-03 |
Bioverativ Therapeutics Inc. |
Verfahren zur virusinaktivierung auf einer säule
|
US20150126458A1
(en)
|
2013-11-05 |
2015-05-07 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
WO2015067791A1
(en)
|
2013-11-11 |
2015-05-14 |
Ascendis Pharma Relaxin Division A/S |
Relaxin prodrugs
|
DE102013113156A1
(de)
|
2013-11-28 |
2015-05-28 |
Freie Universität Berlin |
Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
|
EP4332839A2
(de)
|
2013-12-06 |
2024-03-06 |
Bioverativ Therapeutics Inc. |
Pharmakokinetische werkzeuge für populationen und verwendungen davon
|
EP3102224B1
(de)
*
|
2013-12-20 |
2019-02-20 |
NephroGenesis, LLC. |
Vorrichtungen zur nierendialyse und lipocalin zur verwendung bei der vorbeugung und behandlung von urämie durch dialyse
|
SI3091997T1
(sl)
|
2014-01-10 |
2022-10-28 |
Bioverativ Therapeutics Inc. |
Himerni proteini faktorja VIII in njihova uporaba
|
US9975929B2
(en)
*
|
2014-03-05 |
2018-05-22 |
Merz Pharma Gmbh & Co. Kgaa |
Recombinant clostridial neurotoxins with increased duration of effect
|
MX2016012447A
(es)
|
2014-03-24 |
2017-01-06 |
Biogen Ma Inc |
Formulaciones de factor ix liofilizadas.
|
EP2937096B1
(de)
|
2014-04-23 |
2019-08-21 |
Julius-Maximilians-Universität Würzburg |
Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
EP3197481A1
(de)
|
2014-09-26 |
2017-08-02 |
Bayer Pharma Aktiengesellschaft |
Stabilisierte adrenomedullinderivate und verwendung davon
|
PL3186192T3
(pl)
|
2014-09-30 |
2018-07-31 |
Thena Biotech S.r.l. |
Białko fuzyjne, nanocząstka zbudowana z wielu monomerów wspomnianego białka fuzyjnego oraz ich zastosowanie
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
JP6849590B2
(ja)
|
2014-10-17 |
2021-03-24 |
コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. |
ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
KR102637699B1
(ko)
|
2014-10-24 |
2024-02-19 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
WO2016081884A2
(en)
|
2014-11-21 |
2016-05-26 |
Phasebio Pharmaceuticals, Inc. |
Elp fusion proteins for controlled and sustained release
|
ES2896971T3
(es)
|
2014-11-21 |
2022-02-28 |
Ascendis Pharma Endocrinology Div A/S |
Formas de administración de hormona del crecimiento de acción prolongada
|
WO2016094627A1
(en)
|
2014-12-10 |
2016-06-16 |
S-Aima Holding Company, Llc |
Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
|
CA2976038A1
(en)
|
2015-02-09 |
2016-08-18 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating muscle disease and disorders
|
US10478394B2
(en)
|
2015-03-11 |
2019-11-19 |
Wayne State University |
Compositions and methods to promote wound healing
|
BR112017020986A2
(pt)
|
2015-04-02 |
2018-08-14 |
Molecular Partners Ag. |
proteínas de ligação recombinantes e seu uso
|
TWI726889B
(zh)
|
2015-06-10 |
2021-05-11 |
英商梅迪繆思有限公司 |
蛋白酶抗性之脂化肽
|
TW201718627A
(zh)
*
|
2015-06-11 |
2017-06-01 |
梅茲製藥有限兩合公司 |
重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
|
JP6909203B2
(ja)
|
2015-08-03 |
2021-07-28 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子融合タンパク質及びそれらの製造方法及び使用方法
|
WO2017040344A2
(en)
|
2015-08-28 |
2017-03-09 |
Amunix Operating Inc. |
Chimeric polypeptide assembly and methods of making and using the same
|
ES2863278T3
(es)
|
2015-10-02 |
2021-10-11 |
Silver Creek Pharmaceuticals Inc |
Proteínas terapéuticas biespecíficas para la reparación de tejidos
|
US20190016754A1
(en)
*
|
2015-11-10 |
2019-01-17 |
Proteothera, Inc. |
Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
|
US11401305B2
(en)
*
|
2015-12-22 |
2022-08-02 |
Xl-Protein Gmbh |
Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
|
KR20180104635A
(ko)
|
2015-12-30 |
2018-09-21 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
WO2017118700A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with increased nep stability
|
EP3400020A1
(de)
|
2016-01-08 |
2018-11-14 |
Ascendis Pharma Growth Disorders A/S |
Cnp-prodrugs mit grossen trägergruppen
|
SG11201805026SA
(en)
|
2016-01-08 |
2018-07-30 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with low npr-c binding
|
NZ743488A
(en)
|
2016-01-08 |
2023-02-24 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with low initial npr-b activity
|
AU2017205273C1
(en)
|
2016-01-08 |
2022-12-01 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with reduced side-effects
|
PL3400019T3
(pl)
|
2016-01-08 |
2023-01-23 |
Ascendis Pharma Growth Disorders A/S |
Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
|
ES2929347T3
(es)
|
2016-01-20 |
2022-11-28 |
Merz Pharma Gmbh & Co Kgaa |
Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto
|
JP7217630B2
(ja)
|
2016-02-01 |
2023-02-03 |
バイオベラティブ セラピューティクス インコーポレイテッド |
最適化第viii因子遺伝子
|
EP3423103A1
(de)
|
2016-03-01 |
2019-01-09 |
Ascendis Pharma Bone Diseases A/S |
Pth-prodrugs
|
KR20180114891A
(ko)
|
2016-03-02 |
2018-10-19 |
메르츠 파마 게엠베하 운트 코. 카가아 |
보툴리눔 독소를 포함하는 조성물
|
JP7237590B6
(ja)
|
2016-03-10 |
2023-03-28 |
メドイミューン・リミテッド |
肥満の治療のためのグルカゴン及びglp-1コアゴニスト
|
EP3452097A1
(de)
*
|
2016-05-04 |
2019-03-13 |
Navigo Proteins GmbH |
Zielgerichtete verbindungen zur stellenspezifischen kupplung chemischer einheiten mit einem peptidlinker
|
EP4043010A1
(de)
|
2016-05-06 |
2022-08-17 |
Phasebio Pharmaceuticals, Inc. |
Elp-fusionsproteine zur gesteuerten und verzögerten freisetzung
|
WO2018011266A1
(en)
|
2016-07-13 |
2018-01-18 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
JP7039574B2
(ja)
|
2016-09-29 |
2022-03-22 |
アセンディス ファーマ ボーン ディジージズ エー/エス |
放出制御pth化合物の漸増用量設定
|
CN117257922A
(zh)
|
2016-09-29 |
2023-12-22 |
阿森迪斯药物骨疾病股份有限公司 |
具有低峰-谷比的pth化合物
|
CN109789189B
(zh)
|
2016-09-29 |
2024-01-23 |
阿森迪斯药物骨疾病股份有限公司 |
控释pth化合物的剂量方案
|
CN109843295B
(zh)
|
2016-09-29 |
2022-04-05 |
阿森迪斯药物生长障碍股份有限公司 |
控释cnp激动剂的组合疗法
|
CA3044838A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
IL266972B2
(en)
|
2016-12-02 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
EP3562840A1
(de)
|
2016-12-16 |
2019-11-06 |
Biogen MA Inc. |
Stabilisierter proteolytisch aktivierter wachstumsdifferenzierungsfaktor 11
|
TW201831521A
(zh)
|
2017-01-31 |
2018-09-01 |
美商生物化學醫療公司 |
因子ix融合蛋白以及其製備方法及使用方法
|
NZ756395A
(en)
|
2017-03-16 |
2024-01-26 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
FI3596116T3
(fi)
|
2017-03-16 |
2023-11-09 |
Alpine Immune Sciences Inc |
Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
|
JP2020511144A
(ja)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Pd−l2バリアント免疫調節タンパク質及びその使用
|
AU2018250695A1
(en)
|
2017-04-14 |
2019-11-07 |
Kodiak Sciences Inc. |
Complement factor D antagonist antibodies and conjugates thereof
|
WO2018193122A1
(en)
*
|
2017-04-21 |
2018-10-25 |
Volution Immuno Pharmaceuticals Sa |
Coversin for the treatment of autoimmune blistering diseases
|
WO2018233813A1
(en)
|
2017-06-20 |
2018-12-27 |
Merz Pharma Gmbh & Co. Kgaa |
NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
|
AU2018287145B2
(en)
|
2017-06-21 |
2024-04-18 |
Jazz Pharmaceuticals Ireland Limited |
Modified L-asparaginase
|
WO2018234455A1
(en)
|
2017-06-21 |
2018-12-27 |
Xl-Protein Gmbh |
CONJUGATES OF PROTEIN MEDICINAL PRODUCTS AND PEPTIDES M / S
|
US10174302B1
(en)
|
2017-06-21 |
2019-01-08 |
Xl-Protein Gmbh |
Modified L-asparaginase
|
US11155802B2
(en)
|
2017-07-06 |
2021-10-26 |
Merz Pharma Gmbh & Co. Kgaa |
Recombinant botulinum neurotoxins with increased duration of effect
|
KR20200035130A
(ko)
|
2017-08-09 |
2020-04-01 |
바이오버라티브 테라퓨틱스 인크. |
핵산 분자 및 이의 용도
|
KR20200085777A
(ko)
|
2017-10-18 |
2020-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
|
PT3707261T
(pt)
*
|
2017-11-06 |
2022-07-13 |
Thena Biotech S R L |
Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos
|
EP3483619A1
(de)
*
|
2017-11-13 |
2019-05-15 |
Technische Universität München |
Automatisierte nicht-invasive bestimmung des geschlechts eines embryos und der fertilität eines vogeleis
|
AU2019205273B2
(en)
|
2018-01-03 |
2024-04-04 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
CA3090136A1
(en)
|
2018-02-01 |
2019-08-08 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing factor viii
|
GB201804092D0
(en)
*
|
2018-03-14 |
2018-04-25 |
Imperial Innovations Ltd |
Methods and compositions
|
WO2019185706A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Conjugates
|
MX2020009975A
(es)
|
2018-03-28 |
2020-10-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
|
AU2019246389A1
(en)
|
2018-03-28 |
2020-08-27 |
Ascendis Pharma Oncology Division A/S |
IL-2 conjugates
|
KR20210013584A
(ko)
|
2018-05-18 |
2021-02-04 |
아센디스 파마 본 디지즈 에이/에스 |
Pth 접합체의 개시 용량
|
WO2019222682A1
(en)
|
2018-05-18 |
2019-11-21 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia a
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
PE20210632A1
(es)
|
2018-07-03 |
2021-03-23 |
Bristol Myers Squibb Co |
Formulaciones de fgf-21
|
BR112021002017A2
(pt)
|
2018-08-09 |
2021-05-11 |
Bioverativ Therapeutics Inc. |
moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
|
WO2020053206A1
(en)
|
2018-09-10 |
2020-03-19 |
Volution Immuno Pharmaceuticals Sa |
Coversin for use in the treatment of rheumatic diseases
|
MX2021003543A
(es)
|
2018-09-27 |
2021-06-23 |
Xilio Dev Inc |
Polipeptidos de citocinas enmascaradas.
|
CN111040021B
(zh)
*
|
2018-10-12 |
2023-06-02 |
浙江道尔生物科技有限公司 |
一种改善生物活性蛋白性质的载体蛋白
|
JP2022013959A
(ja)
*
|
2018-11-02 |
2022-01-19 |
味の素株式会社 |
融合タンパク質
|
CN111153965A
(zh)
*
|
2018-11-07 |
2020-05-15 |
浙江道尔生物科技有限公司 |
用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
|
WO2020109978A1
(en)
|
2018-11-26 |
2020-06-04 |
Novartis Ag |
Lpl-gpihbp1 fusion polypeptides
|
AU2019389151A1
(en)
|
2018-11-30 |
2021-06-10 |
Alpine Immune Sciences, Inc. |
CD86 variant immunomodulatory proteins and uses thereof
|
TW202039855A
(zh)
|
2018-12-06 |
2020-11-01 |
美商百歐維拉提夫治療公司 |
表現因子ix之慢病毒載體的用途
|
US20220088149A1
(en)
|
2019-02-11 |
2022-03-24 |
Ascendis Pharma Bone Diseases A/S |
Liquid Pharmaceutical Formulations of PTH Conjugates
|
EP3923906A1
(de)
|
2019-02-11 |
2021-12-22 |
Ascendis Pharma Growth Disorders A/S |
Trockene pharmazeutische formulierungen von cnp-konjugaten
|
US20220088147A1
(en)
|
2019-03-04 |
2022-03-24 |
Ascendis Pharma Endocrinology Division A/S |
Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
|
BR112021020668A2
(pt)
|
2019-04-17 |
2022-01-11 |
Codiak Biosciences Inc |
Composições de exossomos e aav
|
GB201905810D0
(en)
|
2019-04-25 |
2019-06-05 |
Volution Immuno Pharmaceuticals Sa |
Method of treatment
|
EP3986918A1
(de)
|
2019-06-18 |
2022-04-27 |
Bayer Aktiengesellschaft |
Adrenomedullin-analoga zur langzeitstabilisierung und ihre verwendung
|
AU2020295721A1
(en)
|
2019-06-21 |
2021-12-23 |
Ascendis Pharma A/S |
Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds
|
WO2020254602A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
|
CA3143442A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of heteroaromatic nitrogen-comprising compounds
|
CA3152665A1
(en)
|
2019-08-27 |
2021-03-04 |
Tonix Pharma Limited |
Modified tff2 polypeptides
|
JP2023503776A
(ja)
|
2019-09-27 |
2023-02-01 |
ヴォリューション イミュノ ファーマシューティカルズ エスエイ |
造血幹細胞移植後の血栓性微小血管症(hsct-tma)の治療方法
|
US20210113634A1
(en)
|
2019-09-30 |
2021-04-22 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
CN116925237A
(zh)
|
2019-12-31 |
2023-10-24 |
北京质肽生物医药科技有限公司 |
Glp-1和gdf15的融合蛋白以及其缀合物
|
JP2023512427A
(ja)
|
2020-01-03 |
2023-03-27 |
アセンディス ファーマ エー/エス |
分子内転位を受けるコンジュゲート
|
CN113728013B
(zh)
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
WO2021144249A1
(en)
|
2020-01-13 |
2021-07-22 |
Ascendis Pharma Bone Diseases A/S |
Hypoparathyroidism treatment
|
CN116903727A
(zh)
|
2020-05-08 |
2023-10-20 |
高山免疫科学股份有限公司 |
具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法
|
EP4161956A1
(de)
|
2020-06-03 |
2023-04-12 |
Ascendis Pharma Oncology Division A/S |
Il-2-sequenzen und verwendungen davon
|
AU2021319863A1
(en)
|
2020-08-05 |
2023-02-16 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
JP2023538533A
(ja)
|
2020-08-07 |
2023-09-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
線維症の処置のための、ccr2/5拮抗剤と組み合わせたfgf21
|
JP2023540701A
(ja)
|
2020-08-28 |
2023-09-26 |
アセンディス ファーマ オンコロジー ディヴィジョン エー/エス |
グリコシル化il-2タンパク質及びその使用
|
TW202228784A
(zh)
|
2020-09-23 |
2022-08-01 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗peg抗體的化合物
|
IL301411A
(en)
|
2020-09-28 |
2023-05-01 |
Ascendis Pharma Bone Diseases As |
Improving the physical and mental condition of patients with hypoparathyroidism
|
EP4222176A4
(de)
|
2020-09-30 |
2024-02-28 |
Beijing Ql Biopharmaceutical Co Ltd |
Polypeptidkonjugate und verfahren zur verwendung
|
WO2022115597A1
(en)
|
2020-11-25 |
2022-06-02 |
Bristol-Myers Squibb Company |
Methods of treating liver diseases
|
US20240018265A1
(en)
|
2020-12-11 |
2024-01-18 |
Friedrich Miescher Institute For Biomedical Research |
Hdac6 binding proteins and their anti-viral use
|
KR20230124637A
(ko)
|
2020-12-22 |
2023-08-25 |
엑스엘-프로테인 게엠베하 |
구조적으로 무질서한 서열에 대해 특이적인 항체
|
KR20230164709A
(ko)
|
2021-04-01 |
2023-12-04 |
아센디스 파마 에이에스 |
염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도
|
TW202313974A
(zh)
|
2021-06-08 |
2023-04-01 |
瑞典商阿斯特捷利康公司 |
用於治療肝病之組合療法
|
IL310879A
(en)
|
2021-08-23 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Expression system in colovirus
|
AU2022350937A1
(en)
|
2021-09-22 |
2024-03-21 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
WO2023227505A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|
EP4342460A1
(de)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipidnanopartikel mit nukleinsäurefracht
|